All In Biotech

Drug Trial Radar · NCT06315491

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

40

Actual

Start

Sep 25, 2024

Primary completion

Oct 31, 2025

Study completion Oct 31, 2025

Sponsor

Lead sponsor
Cybrexa TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.

Conditions

  • Platinum-resistant Ovarian Cancer
  • Refractory Ovarian Carcinoma

Interventions

  • CBX-12Drug

    CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]Time frame: Randomization to progressive disease (PD) (Up to approximately 21 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TMC Health

    Tucson, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.